↓ Skip to main content

SoLAT (Sorafenib Lenvatinib alternating treatment): a new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid Cancer

Overview of attention for article published in BMC Cancer, October 2018
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
4 Dimensions

Readers on

mendeley
13 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
SoLAT (Sorafenib Lenvatinib alternating treatment): a new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid Cancer
Published in
BMC Cancer, October 2018
DOI 10.1186/s12885-018-4854-z
Pubmed ID
Authors

Soo Young Kim, Seok-Mo Kim, Ho-Jin Chang, Bup-Woo Kim, Yong Sang Lee, Cheong Soo Park, Ki Cheong Park, Hang-Seok Chang

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 13 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 13 100%

Demographic breakdown

Readers by professional status Count As %
Unspecified 2 15%
Student > Doctoral Student 2 15%
Researcher 2 15%
Student > Postgraduate 1 8%
Student > Master 1 8%
Other 5 38%
Readers by discipline Count As %
Medicine and Dentistry 5 38%
Unspecified 3 23%
Biochemistry, Genetics and Molecular Biology 2 15%
Agricultural and Biological Sciences 1 8%
Neuroscience 1 8%
Other 1 8%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 October 2018.
All research outputs
#12,066,685
of 13,610,713 outputs
Outputs from BMC Cancer
#4,141
of 5,098 outputs
Outputs of similar age
#227,956
of 264,342 outputs
Outputs of similar age from BMC Cancer
#1
of 2 outputs
Altmetric has tracked 13,610,713 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 5,098 research outputs from this source. They receive a mean Attention Score of 4.1. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 264,342 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 2 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them